Masthead-Image-Right-min

The End of an Era: FDA is Rescinding Long-Contested LDT Rule for Labs

Withdrawal of LDT Rule Provides Regulatory Clarity and Reimbursement Guidance for Laboratories

Continue Reading...

In our Back to School Era: Grading Revenue Cycle Vendors Like a Pro

Score Your EDI Clearinghouse Partners: Boost Efficiency and Say Goodbye to Low Marks.

Continue Reading...

UnitedHealth Group's Turmoil: The Impact on Labs and Pathology Groups

Rising costs, regulatory scrutiny, and shifting payer dynamics could reshape lab and pathology practice operations and reimbursements.

Continue Reading...

From Red Flags to Readiness: How Labs Can Stay Ahead of Audit Risks

With $1.2B in improper lab payments projected, payers are ramping up audits—putting clinical labs under intense scrutiny.

Continue Reading...

Healthcare's New Law: Preparing for the “One Big Beautiful Bill” Act

The new law brings transformative changes to Medicare, Medicaid, and patient cost-sharing, requiring providers to strategically adapt revenue cycle operations.

Continue Reading...